Japan OKs Bayer PAH drug; Sagent sees profit pop; BioMarin works on pay for performance model;

@FiercePharma: Sanofi names Paris-trained Olivier Brandicourt CEO. He will begin at Sanofi April 2. Report | Follow @FiercePharma

@CarlyHFierce: ICYMI earlier: Protein Sciences halts Connecticut expansion in response to governor's use of rival flu shot. FierceVaccines story | Follow @CarlyHFierce

> Bayer Healthcare says Adempas, a drug is developed with Merck & Co. has been approved in Japan for the treatment of two kinds of pulmonary arterial hypertension (PAH). Release

> Sagent Pharmaceuticals ($SGNT) reported a 32% increase in revenues and a 41% rise in profit for 2014. Release

> The Indian Pharmaceutical Association is concerned that an overhaul of the industry by the new government will take away too much authority from state regulators. Report

> Germany will encourage the development of new antibiotics that can fight antibiotic-resistant "superbugs." Story

Medical Device News

@FierceMedDev: Integra LifeSciences lays off 49 in Massachusetts as part of facility consolidation drive. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ $GE response GE recalls 10,000+ MRI systems after FDA deems them potentially deadly, citing poor training. Article | Follow @VarunSaxena2

@EmilyWFierce: Check out our weekly roundup of FierceLifeSciences news here! Newsletter | Follow @EmilyWFierce

> KKR-backed Panasonic Healthcare to buy Bayer diabetes device biz for as much as $2.3B. More

> 23andMe nabs FDA marketing clearance for direct-to-consumer genetic carrier test. Story

> New studies shed light on power morcellator devices in surgical procedures. Article

Biotech News

@FierceBiotech: EuroBiotech Report: Novartis makes Israel a priority, U.K. dreams up Alzheimer's R&D hub, Shire defends tax model. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: I love this Pronutria story. VC insiders, star scientist, homeostasis focus on oral biologics. It's what makes Boston/Cambridge special. Article | Follow @JohnCFierce

@DamianFierce: Cerecor is repurposing an old $LLY antidepressant for addiction. Release | Follow @DamianFierce

> Ariad activists rabble for Berger's job and mount a proxy fight. Story

> Novo Nordisk's game-changing oral diabetes drug clears Phase II. Article

> Biotech bonanza helps Bessemer roll out a $1.6B venture fund. Report

And Finally... BioMarin Pharmaceutical ($BMRN) and Sangamo BioSciences ($SGMO) are among companies working on payment plans for gene therapies that would provide large payouts, over a number of years, but only if they are effective. Story

Suggested Articles

If Pfizer wants Lorbrena to be a true follow-up to Xalkori, it has to win a first-line OK in ALK-positive lung cancer. And it just got closer.

Eylea sales dropped 4% to $1.11 billion amid the pandemic, but still beat expectations. And meanwhile, Regeneron's COVID antibody is advancing.

Johnson & Johnson inked a $10-per-dose vaccine supply deal with the U.S. for 100 million initial doses, with 200 million more available down the line.